| This is the talk page for discussing improvements to the Dabrafenib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Dabrafenib.
|
Cost
edit[1] says "In the US, the wholesale acquisition cost of Tafinlar is $7,600 for a 30-day supply" - Rod57 (talk) 13:19, 22 August 2014 (UTC)
Benefit
edit[2] says "The BRAF inhibitor prolonged progression-free survival by 2.4 months, the FDA said." - Rod57 (talk) 13:28, 22 August 2014 (UTC)